Contact

Click here for a confidential contact or call:

1-212-350-2774

Archive

Page 9 of 13

DaVita Rx Agrees to Pay $63.7 Million to Resolve False Claims Act Allegations

Posted  12/15/17
By the C|C Whistleblower Lawyer Team DaVita Rx LLC, a nationwide pharmacy that specializes in serving patients with severe kidney disease, agreed to pay a total of $63.7 million to resolve False Claims Act allegations relating to improper billing practices and unlawful financial inducements to federal healthcare program beneficiaries, the Justice Department announced today.  DaVita Rx is based in Coppell,...

Drug Wholesaler Settles FCA Suit For $625M

Posted  11/27/17
By the C|C Whistleblower Lawyer Team AmerisourceBergen, a Pennsylvania-based company that provides drug distribution and related services, has agreed to pay $625M to settle an FCA case that claimed that a pre-filled syringe program at one of its subsidiaries violated several federal laws.  The subsidiary, Medical Initiatives Inc. (MII), closed in 2014, but was responsible for moving cancer medications from glass...

Founder and Owner of Pharmaceutical Company Insys Arrested and Charged with Racketeering

Posted  10/27/17
By the C|C Whistleblower Lawyer Team The founder and majority owner of Insys Therapeutics Inc., was arrested and charged with leading a nationwide conspiracy to profit by using bribes and fraud to cause the illegal distribution of a Fentanyl spray intended for cancer patients experiencing breakthrough pain. "More than 20,000 Americans died of synthetic opioid overdoses last year, and millions are addicted to...

Fraudster of the Week -- TRICARE Fraudster Joseph Baumiller

Posted  10/20/17
By the C|C Whistleblower Lawyer Team On Tuesday, 38-year-old Joseph Baumiller of Dallas, Texas pleaded guilty to one count of conspiracy to defraud TRICARE, the health care program serving military members and their families. Baumiller, the former president of Trilogy Pharmacy, admitted to conspiring with several marketers, physicians, and other pharmacists to orchestrate a scheme involving the payment of kickbacks...

Former DEA Agent Alleges Opioid Crisis Fueled by Drug Companies

Posted  10/16/17
By the C|C Whistleblower Lawyer Team As reported in CBS News, the Washington Post and other news outlets A former employee of the Drug Enforcement Administration (DEA) said in an interview that efforts to stem the growing opioid epidemic in the U.S. were derailed by pressure from large pharmaceutical companies and Congress. Joe Rannazzisi told CBS that major distributors allowed drugs to be obtained by rogue...

Aegerion Pharmaceuticals Will Pay More Than $40 Million to Resolve Investigations Into Its Marketing and Sales Practices

Posted  09/25/17
Aegerion Pharmaceuticals will plead guilty to charges concerning its prescription drug, Juxtapid, the Department of Justice announced on Friday.  According to the Justice Department’s press release: Aegerion introduced Juxtapid into interstate commerce that was misbranded because, among other things, Aegerion failed to comply with a Risk Evaluation and Mitigation Strategy (REMS).  The resolution also...

Health Insurers May Be Contributing to the Opioid Crisis in the United States

Posted  09/18/17
By the C|C Whistleblower Lawyer Team An article in the New York Times describes the role health insurers may be playing in perpetuating the opioid crisis in the United States. The argument is that health insurers are limiting access to pain medications that have a lower risk of dependency. The reason is that opioid drugs are generally cheaper and less risky alternatives are more expensive. The New York State...

DOJ Catch of the Week -- Novo Nordisk Inc.

Posted  09/8/17
By the C|C Whistleblower Lawyer Team This week's Department of Justice "Catch of the Week" goes to Novo Nordisk Inc. On Tuesday, the company agreed to pay $58.65 million to settle charges it violated the False Claims Act and Food, Drug, and Cosmetic Act by failing to comply with the FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) for its Type II diabetes medication Victoza. The New Jersey based...

Mylan Agrees to Pay $465 Million in a False Claims Act Settlement

Posted  08/21/17
By the C|C Whistleblower Lawyer Team Last Friday, the Department of Justice (“DOJ”) announced a $465 million settlement with Mylan, Inc. to resolve claims that it violated the False Claim Act. The suit was brought by a whistleblower under the False Claims Act qui tam provisions and involved the alleged improper misclassification of the EpiPen as a generic drug to avoid paying rebates owed mainly to Medicaid....

DOJ Catch of the Week -- Mylan

Posted  08/18/17
By the C|C Whistleblower Lawyer Team This week's Department of Justice "Catch of the Week" goes to Mylan Inc. and Mylan Specialty L.P. Yesterday, the pharmaceutical companies agreed to pay $465 million to settle charges they violated the False Claims Act by purposely misclassifying EpiPen as a generic drug to avoid paying higher Medicaid rebates. In announcing the settlement, the government stressed its "unwavering...
1 6 7 8 9 10 11 12 13